Alecensa (alectinib) — Medica
Pediatric Diffuse High-Grade Gliomas
Initial criteria
- age ≤ 21 years
- anaplastic lymphoma kinase (ALK)-positive disease
- used for adjuvant treatment AND tumor is not diffuse midline glioma, H3 K27-altered or pontine location OR used for recurrent or progressive disease
Approval duration
1 year